Relationships Among Morphine Metabolism, Pain and Side Effects During Long-Term Treatment
Tóm tắt
Từ khóa
Tài liệu tham khảo
Reisine, 1996, Opioid analgesics and antagonists, 521
Lötsch, 1999, Pharmacokinetic modeling of M6G formation after oral administration of morphine in healthy volunteers, Anesthesiology, 90, 1026, 10.1097/00000542-199904000-00016
Tan, 1989, Characteristics of the gastrointestinal absorption of morphine in rats, Chem Pharm Bull (Tokyo), 37, 168, 10.1248/cpb.37.168
Vater, 1984, Pharmacokinetics and analgesic effect of slow-release oral morphine sulphate in volunteers, Br J Anaesth, 56, 821, 10.1093/bja/56.8.821
Säwe, 1981, Morphine kinetics in cancer patients, Clin Pharmacol Ther, 30, 629, 10.1038/clpt.1981.214
Säwe, 1985, Oral morphine in cancer patients, Br J Clin Pharmacol, 19, 495, 10.1111/j.1365-2125.1985.tb02675.x
Osborne, 1990, Morphine and metabolite behavior after different routes of morphine administration, Clin Pharmacol Ther, 47, 12, 10.1038/clpt.1990.2
Yeh, 1977, Isolation and identification of morphine 3- and 6-glucuronides, morphine 3,6-diglucuronide, morphine 3-ethereal sulfate, normorphine and normorphine 6-glucuronide as morphine metabolites in humans, J Pharm Sci, 66, 1288, 10.1002/jps.2600660921
Boerner, 1975, The metabolism of morphine and heroin in man, Drug Metab Rev, 4, 39, 10.3109/03602537508993748
Mitchell, 1991, Forensic drug testing for opiates. II. Metabolism and excretion rate of morphine in humans after morphine administration, J Anal Toxicol, 15, 49, 10.1093/jat/15.2.49
Hasselström, 1993, Morphine pharmacokinetics and metabolism in humans, Clin Pharmacokinet, 24, 344, 10.2165/00003088-199324040-00007
Yeh, 1975, Urinary excretion of morphine and its metabolites in morphine-dependent subjects, J Pharmacol Exp Ther, 192, 201
Säwe, 1986, High-dose morphine and methadone in cancer patients. Clinical pharmacokinetic considerations of oral treatment, Clin Pharmacokinet, 11, 87, 10.2165/00003088-198611020-00001
de Wildt, 1999, Glucuronidation in humans. Pharmacogenetic and developmental aspects, Clin Pharmacokinet, 36, 439, 10.2165/00003088-199936060-00005
Bodenham, 1989, Extrahepatic morphine metabolism in man during the anhepatic phase of orthotopic liver transplantation, Br J Anaesth, 63, 380, 10.1093/bja/63.4.380
Yue, 1988, Glucuronidation of morphine in human kidney microsomes, Pharmacol Toxicol, 63, 337, 10.1111/j.1600-0773.1988.tb00965.x
Pacifici, 1986, Presystemic glucuronidation of morphine in humans and rhesus monkeys, Xenobiotica, 16, 123, 10.3109/00498258609043514
Mikus G, von Richter O, Hofmann U, et al. Glucuronidation of morphine in human liver and small intestine. Book of Abstracts, 9th World Congress on Pain. Vienna, 1999:335.
Wahlström, 1988, Human brain metabolism of morphine and naloxone, Pain, 35, 121, 10.1016/0304-3959(88)90219-9
King, 1999, Expression of UDP-glucuronosyltransferases (UGTs) 2B7 and 1A6 in the human brain and identification of 5-hydroxytryptamine as a substrate, Arch Biochem Biophys, 365, 156, 10.1006/abbi.1999.1155
Coughtrie, 1989, The enantioselective glucuronidation of morphine in rats and humans. Evidence for the involvement of more than one UDP-glucuronosyltransferase isoenzyme, Biochem Pharmacol, 38, 3273, 10.1016/0006-2952(89)90625-4
Wahlström, 1988, Human liver morphine UDP-glucuronyl transferase enantioselectivity and inhibition by opioid congeners and oxazepam, Br J Pharmacol, 94, 864, 10.1111/j.1476-5381.1988.tb11598.x
Coffman, 1997, Human UGT2B7 catalyzes morphine glucuronidation, Drug Metab Disp, 25, 1
Crotty, 1989, Hepatic extraction of morphine is impaired in cirrhosis, Eur J Clin Pharmacol, 36, 501, 10.1007/BF00558076
Mazoit, 1990, Extrahepatic metabolism of morphine occurs in humans, Clin Pharmacol Ther, 48, 613, 10.1038/clpt.1990.203
Smith, 1999, Cerebrospinal fluid and plasma concentrations of morphine, morphine-3-glucuronide and morphine-6-glucuronide in patients before and after initiation of intracerebroventricular morphine for cancer pain management, Anesth Analg, 88, 109, 10.1213/00000539-199901000-00021
Sandouk, 1991, Presence of morphine metabolites in human cerebrospinal fluid after intracerebroventricular administration of morphine, Eur J Drug Metab Pharmacokinet, 3, 166
Wolff, 1995, Morphine and morphine metabolite concentrations in cerebrospinal fluid and plasma in cancer pain patients after slow-release oral morphine administration, Pain, 62, 147, 10.1016/0304-3959(94)00268-J
Janicki, 1991, The route of prolonged morphine administration affects the pattern of its metabolites in the urine of chronically treated patients, Eur J Clin Chem Clin Biochem, 29, 391
Osborne, 1993, The pharmacokinetics of morphine and morphine glucuronides in kidney failure, Clin Pharmacol Ther, 54, 158, 10.1038/clpt.1993.127
Patwardhan, 1981, Normal metabolism of morphine in cirrhosis, Gastroenterology, 81, 1006, 10.1016/S0016-5085(81)80005-4
Mazoit, 1987, Pharmacokinetics of unchanged morphine in normal and cirrhotic subjects, Anesth Analg, 66, 293, 10.1213/00000539-198704000-00001
Hasselström, 1990, The metabolism and bioavailability of morphine in patients with severe liver cirrhosis, Br J Clin Pharmacol, 29, 289, 10.1111/j.1365-2125.1990.tb03638.x
Hoyumpa, 1991, Is glucuronidation truly preserved in patients with liver disease?, Hepatology, 13, 786, 10.1002/hep.1840130428
Wolff, 1988, Influence of renal function on the elimination of morphine and morphine glucuronides, Eur J Clin Pharmacol, 34, 353, 10.1007/BF00542435
Säwe, 1987, Kinetics of morphine in patients with renal failure, Eur J Clin Pharmacol, 32, 377, 10.1007/BF00543973
Pauli-Magnus, 1999, Pharmacokinetics of morphine and its glucuronides following intravenous administration of morphine in patients undergoing continuous ambulatory peritoneal dialysis, Nephrol Dial Transplant, 14, 903, 10.1093/ndt/14.4.903
Milne, 1992, The influence of renal function on the renal clearance of morphine and its glucuronide metabolites in intensive-care patients, Br J Clin Pharmacol, 34, 53, 10.1111/j.1365-2125.1992.tb04107.x
D'Honneur, 1994, Plasma and cerebrospinal fluid concentrations of morphine and morphine glucuronides after oral morphine, Anesthesiology, 81, 87, 10.1097/00000542-199407000-00013
Peterson, 1990, Plasma levels of morphine and morphine glucuronides in the treatment of cancer pain, Eur J Clin Pharmacol, 38, 121, 10.1007/BF00265969
Tiseo, 1995, Morphine-6-glucuronide concentrations and opioid-related side effects, Pain, 61, 47, 10.1016/0304-3959(94)00148-8
Hanna, 1993, Morphine-6-glucuronide disposition in renal impairment, Br J Anaesth, 70, 511, 10.1093/bja/70.5.511
Osborne, 1986, Morphine intoxication in renal failure, Br Med J, 292, 1548, 10.1136/bmj.292.6535.1548
Bodd, 1990, Morphine-6-glucuronide might mediate the prolonged opioid effect of morphine in acute renal failure, Human Exp Toxicol, 9, 317, 10.1177/096032719000900509
Hasselström, 1989, Long lasting respiratory depression induced by morphine-6-glucuronide?, Br J Clin Pharmacol, 27, 515, 10.1111/j.1365-2125.1989.tb05401.x
Sjøgren, 1993, Myoclonic spasms during treatment with high doses of intravenous morphine in renal failure, Acta Anaesthesiol Scand, 37, 780, 10.1111/j.1399-6576.1993.tb03809.x
Zhou, 1993, Ethnic differences in response to morphine, Clin Pharmacol Ther, 54, 507, 10.1038/clpt.1993.182
Aasmundstad, 1998, Influence of ranitidine on the morphine-3-glucuronide to morphine-6-glucuronide ratio after oral administration of morphine in humans, Hum Exp Toxicol, 17, 347
Wahlström, 1994, Tricyclic antidepressants inhibit opioid receptor binding in human brain and hepatic morphine glucuronidation, Pharmacol Toxicol, 75, 23, 10.1111/j.1600-0773.1994.tb00319.x
Ventafridda, 1987, Antidepressants increase bioavailability of morphine in cancer patients, Lancet, 1, 1204, 10.1016/S0140-6736(87)92172-6
Choonara, 1989, Morphine metabolism in children, Br J Clin Pharmacol, 28, 599, 10.1111/j.1365-2125.1989.tb03548.x
Lynn, 1998, Clearance of morphine in postoperative infants during intravenous infusion, Anesth Analg, 86, 958, 10.1213/00000539-199805000-00008
McRorie, 1992, The maturation of morphine clearance and metabolism, Am J Dis Child, 146, 972
Kaiko, 1980, Age and morphine analgesia in cancer patients with postoperative pain, Clin Pharmacol Ther, 28, 823, 10.1038/clpt.1980.241
Moore, 1990, Differences in epidural morphine requirements between elderly and young patients after abdominal surgery, Anesth Analg, 70, 316, 10.1213/00000539-199003000-00014
Gourlay, 1991, The reproducibility of bioavailability of oral morphine from solution under fed and fasted conditions, J Pain Symptom Manage, 6, 431, 10.1016/0885-3924(91)90042-3
Säwe, 1983, Morphine metabolism in cancer patients on increasing oral doses—no evidence for autoinduction or dose-dependence, Br J Clin Pharmacol, 16, 85, 10.1111/j.1365-2125.1983.tb02148.x
Vermeire, 1998, Variability of morphine disposition during long-term subcutaneous infusion in terminally ill cancer patients, Eur J Clin Pharmacol, 53, 325, 10.1007/s002280050387
Carrupt, 1991, Morphine-6-glucuronide and morphine-3-glucuronide as molecular chameleons with unexpected lipophilicity, J Med Chem, 34, 1272, 10.1021/jm00108a005
Lötsch, 1996, Pharmacokinetics of morphine and its glucuronides after intravenous infusion of morphine and morphine-6-glucuronide in healthy volunteers, Clin Pharmacol Ther, 60, 316, 10.1016/S0009-9236(96)90058-2
Hanna, 1991, Disposition of morphine-6-glucuronide and morphine in healthy volunteers, Br J Anaesth, 66, 103, 10.1093/bja/66.1.103
Hoskin, 1989, The bioavailability and pharmakokinetics of morphine after intravenous, oral and buccal administration in healthy volunteers, Br J Clin Pharmacol, 27, 499, 10.1111/j.1365-2125.1989.tb05399.x
Gourlay, 1994, A comparison of Kapanol (a new sustained-release morphine formulation), MST Continus and morphine solution in cancer patients, 631
Poulain, 1988, Relative bioavailability of controlled release morphine tablets (MST Continus) in cancer patients, Br J Anaesth, 61, 569, 10.1093/bja/61.5.569
Osborne, 1986, Morphine intoxication in renal failure, Br Med J, 292, 1548, 10.1136/bmj.292.6535.1548
Christrup, 1999, Steady-state kinetics and dynamics of morphine in cancer patients. Is sedation related to the absorption rate of morphine?, J Pain Symptom Manage, 18, 164, 10.1016/S0885-3924(99)00068-8
Stain, 1995, Analgesic response and plasma and brain extracellular fluid pharmacokinetics of morphine and morphine-6-beta-D-glucuronide in the rat, J Pharmacol Exp Ther, 274, 852
Aasmundstad, 1995, Distribution of morphine 6-glucuronide and morphine across the blood-brain barrier in awake, freely moving rats investigated by in vivo microdialysis sampling, J Pharmacol Exp Ther, 275, 435
Barjavel, 1994, Morphine and morphine metabolite kinetics in the rat brain as assessed by transcortical microdialysis, Life Sci, 55, 1301, 10.1016/0024-3205(94)90069-8
Murphey, 1994, Diffusion of morphine-6-beta-D-glucuronide into the neonatal guinea pig brain during drug-induced respiratory depression, J Pharmacol Exp Ther, 271, 118
Wu, 1997, Blood-brain barrier permeability to morphine-6-glucuronide is markedly reduced compared with morphine, Drug Metab Dispos, 25, 768
Bickel, 1996, Poor permeability of morphine 3-glucuronide and morphine 6-glucuronide through the blood-brain barrier in the rat, J Pharmacol Exp Ther, 278, 107
Thompson, 2000, Opiate-induced analgesia is increased and prolonged in mice lacking P-glycoprotein, Anesthesiology, 92, 1392, 10.1097/00000542-200005000-00030
Huwyler, 1996, Evidence for P-glycoprotein-modulated penetration of morphine-6-glucuronide into brain capillary endothelium, Br J Pharmacol, 118, 1879, 10.1111/j.1476-5381.1996.tb15619.x
Callaghan, 1993, Synthetic and natural opiates interact with P-glycoprotein in multidrug-resistant cells, J Biol Chem, 268, 16059, 10.1016/S0021-9258(18)82357-2
Goucke, 1994, Concentrations of morphine, morphine-6-glucuronide and morphine-3-glucuronide in serum and cerebrospinal fluid following morphine administration to patients with morphine-resistant pain, Pain, 56, 145, 10.1016/0304-3959(94)90088-4
Van Dongen, 1994, Morphine and morphine-glucuronide concentrations in plasma and CSF during long-term administration of oral morphine, Br J Clin Pharmacol, 38, 271, 10.1111/j.1365-2125.1994.tb04352.x
Portenoy, 1991, Chronic morphine therapy for cancer pain, Neurology, 41, 1457, 10.1212/WNL.41.9.1457
Wolff, 1996, Concentrations of morphine and morphine metabolites in CSF and plasma during continuous subcutaneous morphine administration in cancer pain patients, Pain, 68, 209, 10.1016/S0304-3959(96)03102-8
Pasternak, 1987, Morphine-6-glucuronide, a potent mu agonist, Life Sci, 41, 2845, 10.1016/0024-3205(87)90431-0
Barlett, 1994, Pharmacology of morphine and morphine-3-glucuronide at opioid, excitatory amino acid, GABA and glycine binding sites, Pharmacol Toxicol, 75, 73, 10.1111/j.1600-0773.1994.tb00327.x
Hucks, 1992, Explanation at the opioid receptor level for differing toxicity of morphine and morphine-6-glucuronide, Br J Cancer, 65, 122, 10.1038/bjc.1992.23
Frances, 1992, Further evidence that morphine-6β-glucuronide is a more potent opioid agonist than morphine, J Pharmacol Exp Ther, 262, 25
Paul, 1989, Pharmacological characterization of morphine-6 beta-glucuronide, a very potent morphine metabolite, J Pharmacol Exp Ther, 251, 477
Stain-Texier, 1999, Elevated concentrations of morphine 6-beta-D-glucuronide in brain extracellular fluid despite low blood-brain barrier permeability, Br J Pharmacol, 128, 917, 10.1038/sj.bjp.0702873
Motamed, 2000, Preemptive intravenous morphine-6-glucuronide is ineffective for postoperative pain relief, Anesthesiology, 92, 355, 10.1097/00000542-200002000-00015
Lötsch, 1997, Lack of analgesic activity of morphine-6-glucuronide after short-term intravenous administration in healthy volunteers, Anesthesiology, 87, 1348, 10.1097/00000542-199712000-00014
Hanna, 1990, Analgesic efficacy and CSF pharmacokinetics of intrathecal morphine-6-glucuronide, Br J Anaesth, 64, 547, 10.1093/bja/64.5.547
Grace, 1996, A comparison of intrathecal morphine-6-glucuronide and intrathecal morphine sulfate as analgesics for total hip replacement, Anesth Analg, 83, 1055, 10.1213/00000539-199611000-00027
Thompson, 1995, Respiratory depression following morphine and morphine-6-glucuronide in normal subjects, Br J Clin Pharmacol, 40, 145
Osborne, 1992, The analgesic activity of morphine-6-glucuronide, Br J Clin Pharmacol, 34, 130, 10.1111/j.1365-2125.1992.tb04121.x
Peat S, Hanna M, Durcan T, Fung M. Morphine-6-glucuronide in postoperative pain. Book of Abstracts, 9th World Congress on Pain, Vienna, Austria, 1999:335.
Faura, 1996, Morphine and morphine-6-glucuronide plasma concentrations and effect in cancer pain, J Pain Symptom Manage, 11, 95, 10.1016/0885-3924(95)00148-4
Portenoy, 1992, The metabolite morphine-6-glucuronide contributes to the analgesia produced by morphine infusion in patients with pain and normal renal function, Clin Pharmacol Ther, 51, 422, 10.1038/clpt.1992.42
Klepstad, 2000, Start of oral morphine to cancer patients, Eur J Clin Pharmacol, 55, 713, 10.1007/s002280050003
Dennis, 1999, Analgesic responses to intrathecal morphine in relation to CSF concentrations of morphine-3,β-glucuronide and morphine-6,β-glucuronide, Life Sci, 64, 1725, 10.1016/S0024-3205(99)00110-1
Somogyi, 1993, Plasma concentrations and renal clearance of morphine, morphine-3-glucuronide and morphine-6-glucuronide in cancer patients receiving morphine, Clin Pharmacokinet, 24, 413, 10.2165/00003088-199324050-00005
Samuelsson, 1993, CSF and plasma concentrations of morphine and morphine glucuronides in cancer patients receiving epidural morphine, Pain, 52, 179, 10.1016/0304-3959(93)90129-D
Hoffman, 1997, A pharmacodynamic study of morphine and its glucuronide metabolites after single morphine dosing in cancer patients with pain, Cancer Invest, 15, 542, 10.3109/07357909709047595
Gong, 1991, Antinociceptive and ventilatory effects of the morphine metabolites, Eur J Pharmacol, 193, 47, 10.1016/0014-2999(91)90199-Z
Pelligrino, 1989, Ventilatory effects of fourth cerebroventricular infusions of morphine-6- or morphine-3-glucuronide in the awake dog, Anesthesiology, 71, 936, 10.1097/00000542-198912000-00018
Ling, 1985, Separation of opioid analgesia from respiratory depression, J Pharmacol Exp Ther, 232, 149
Hagen, 1991, Chronic nausea and morphine-6-glucuronide, J Pain Symptom Manage, 6, 125, 10.1016/0885-3924(91)90961-3
Ashby, 1997, Plasma morphine and glucuronide (M3G and M6G) concentrations in hospice patients, J Pain Symptom Manage, 14, 157, 10.1016/S0885-3924(97)00020-1
Westerling, 1995, Plasma concentrations of morphine, morphine-3-glucuronide and morphine-6-glucuronide after intravenous and oral administration to healthy volunteers, Ther Drug Monit, 17, 287, 10.1097/00007691-199506000-00013
Andersen, 2002, Pain, sedation and morphine metabolism in cancer patients during long-term treatment with sustained release morphine, Palliat Med, 16, 107, 10.1191/0269216302pm512oa
Faura, 1996, Lack of morphine-6-glucuronide antinociception after morphine treatment. Is morphine-3-glucuronide involved?, Pain, 65, 25, 10.1016/0304-3959(95)00198-0
Gong, 1992, Morphine-3-glucuronide may functionally antagonize morphine-6-glucuronide induced antinociception and ventilatory depression in the rat, Pain, 48, 249, 10.1016/0304-3959(92)90065-J
Smith, 1990, Morphine-3-glucuronide—a potent antagonist of morphine analgesia, Life Sci, 47, 579, 10.1016/0024-3205(90)90619-3
Bian, 1996, Effects of morphine-3-glucuronide on the antinociceptive activity of peptide and nonpeptide opioid receptor agonists in mice, Peptides, 17, 1415, 10.1016/S0196-9781(96)00215-X
Hewett, 1993, Lack of effect of morphine-3-glucuronide on the spinal antinociceptive actions of morphine in the rat, Pain, 53, 59, 10.1016/0304-3959(93)90056-U
Quellet, 1997, Effect of prior morphine-3-glucuronide exposure on morphine disposition and antinociception, Biochem Pharmacol, 53, 1451, 10.1016/S0006-2952(97)00086-5
Bowsher, 1993, Paradoxical pain. When metabolites of morphine are in the wrong ratio, Br Med J, 306, 473, 10.1136/bmj.306.6876.473
Labella, 1979, Morphine derivatives with diminished opiate receptor potency show enhanced central excitatory activity, Brain Res, 174, 263, 10.1016/0006-8993(79)90849-7
Barlett, 1994, The excitatory effects of morphine-3-glucuronide are attenuated by LY274614, a competitive NMDA receptor antagonist, and by midazolam, an agonist at the benzodiazepine site on the GABAA receptor complex, Life Sci, 54, 687, 10.1016/0024-3205(94)00552-4
Woolf, 1981, Intrathecal high dose morphine produces hyperalgesia in the rat, Brain Res, 209, 491, 10.1016/0006-8993(81)90176-1
Yaksh, 1986, High doses of spinal morphine produce a nonopiate receptor-mediated hyperesthesia, Anesthesiology, 64, 590, 10.1097/00000542-198605000-00008
Yaksh, 1988, Pharmacology of the allodynia in rats evoked by high dose intrathecal morphine, J Pharmacol Exp Ther, 244, 501
Shohami, 1986, A new animal model for action myoclonus, Adv Neurol, 43, 545
Lufty, 1994, Inhibition of clonic seizure-like excitatory effects induced by intrathecal morphine using two NMDA receptor antagonists, Eur J Pharmacol, 252, 261, 10.1016/0014-2999(94)90171-6
Sjøgren, 1998, Is development of hyperalgesia, allodynia and myoclonus related to morphine metabolism during long-term administration?, Acta Anaesthesiol Scand, 42, 1070, 10.1111/j.1399-6576.1998.tb05378.x
Hagen, 1997, Strychnine-like multifocal myoclonus and seizures in extremely high-dose opioid administration, J Pain Symptom Manage, 14, 51, 10.1016/S0885-3924(97)00001-8
Rozan, 1995, Epidural and intravenous opioid-induced neuroexcitation, Anesthesiology, 83, 860, 10.1097/00000542-199510000-00027
Kronenberg, 1998, Epileptic seizure associated with intracerebroventricular and intrathecal morphine bolus, Pain, 75, 383, 10.1016/S0304-3959(97)00173-5